Document Detail


Ultra-short-course chemotherapy for spinal tuberculosis: five years of observation.
MedLine Citation:
PMID:  23053764     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: This study aimed to explore the feasibility of ultra-short-course chemotherapy in the treatment of spinal tuberculosis.
METHODS: One hundred and eighty-five patients with confirmed spinal tuberculosis and surgical indication were included. The chemotherapy regimen was 2SHRZ/XHRZ. According to the duration of the chemotherapy, the patients were divided into two groups, the ultra-short-course chemotherapy group with an average duration of 4.5 months, and the standard chemotherapy group with an average duration of 9 months. The same surgery was performed for patients in the two groups.
RESULTS: The duration of the follow-up ranged from 61 to 87 months, with an average of 69.1 months. Erythrocyte sedimentation rate and C-reactive protein, kyphosis and nerve function, recovery of work, and activities of daily living were not significantly different between the two groups before or after treatment; however, the aforementioned indices were significantly different before and after treatment within groups. There was no significant difference in postoperative bone graft healing between the two groups. The drug side effects were significantly different between the two groups.
CONCLUSIONS: With thorough focus debridement, bone grafting, and internal fixation, the efficacy of ultra-short chemotherapy was similar to that of standard chemotherapy for the treatment of spinal tuberculosis. The ultra-short-course chemotherapy can shorten the course of treatment and reduce drug side effects.
Authors:
Zili Wang; Jiandang Shi; Guangqi Geng; Hongyan Qiu
Related Documents :
24369214 - A comparison of results by sequential and concurrent chemo radiotherapy in locally adva...
21876084 - Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer p...
20159824 - Phase i clinical trial of the cyp17 inhibitor abiraterone acetate demonstrating clinica...
21907984 - Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location.
12200354 - Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a s...
24042334 - Significance of resection margin as a risk factor for local control of early stage brea...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2012-10-11
Journal Detail:
Title:  European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society     Volume:  22     ISSN:  1432-0932     ISO Abbreviation:  Eur Spine J     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-28     Completed Date:  2013-07-22     Revised Date:  2014-02-04    
Medline Journal Info:
Nlm Unique ID:  9301980     Medline TA:  Eur Spine J     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  274-81     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibiotics, Antitubercular / administration & dosage,  therapeutic use*
Bone Transplantation
Cervical Vertebrae / surgery*
Debridement
Drug Administration Schedule
Female
Humans
Lumbar Vertebrae / surgery*
Male
Middle Aged
Rifampin / administration & dosage,  therapeutic use*
Thoracic Vertebrae / surgery*
Treatment Outcome
Tuberculosis, Spinal / drug therapy*,  surgery
Chemical
Reg. No./Substance:
0/Antibiotics, Antitubercular; VJT6J7R4TR/Rifampin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Isolated posterior instrumentation for selected cases of thoraco-lumbar spinal tuberculosis without ...
Next Document:  In vitro toxicity and antidiabetic activity of a newly developed polyherbal formulation (MAC-ST/001)...